PCM
AMRI

Piermont Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Piermont Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-150,330
Closed -$2.79M – 176
2014
Q1 		$2.79M Buy
150,330
+4,070
+3% +$56K 1.35% 8
2013
Q4 		$1.47M Buy
+146,260
New +$1.77M 0.74% 84

Other funds holding AMRI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Evercore Wealth Management
Evercore Wealth Management New York $7.07B AUM 24.72% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
American Capital Management New York $2.23B AUM 28.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Piermont Capital Management's AMRI Position: Q2 2014 in Review

Piermont Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q2 2014, closing a stake of 150,330 shares — an estimated $2.79M sold.

Piermont Capital Management first reported a position in AMRI in Q4 2013 and held it in 2 quarters. The position peaked at $2.79M in Q1 2014. 132 funds tracked by Wall St. Rank hold AMRI as of Q2 2014.

  • Piermont Capital Management reported no remaining Albany Molecular Research Inc position as of Q2 2014 after selling out during the quarter.
  • Piermont Capital Management sold 150,330 Albany Molecular Research Inc shares in Q2 2014, an estimated $2.79M.
  • Piermont Capital Management first reported a position in Albany Molecular Research Inc in Q4 2013 and held it in 2 quarters.
  • Piermont Capital Management's Albany Molecular Research Inc position peaked at $2.79M in Q1 2014.
  • 132 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2014.

Based on Piermont Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.